All News
COVIDs Extended Risk for Rheumatic Disease
d
EurekAlert!
Annals of Internal Medicine reports a large, binational study finding SARS-CoV-2 infection was associated with an increased risk for autoimmune inflammatory rheumatic diseases (AIRDs) that extends up to 12 months after infe
Read Article
Cross-sectional multicenter study of 500 ax-SpA pts on biologics found 25% w/ Irritable Bowel Syndrome (IBS) that was linked to being Female gender, unemployed, higher BASDAI & BASFI, multiple biologics, FM , anxiety, depression & lower physical activity. https://t.co/RSKVcXZwLt https://t.co/RGsw3fHr3H
Dr. John Cush RheumNow ( View Tweet)
An assessment of screening for latent tuberculosis in patients initiating b/tsDMARD therapy found over 1 in 3 new b/tsDMARD users did not receive TB screening within recommended time window, as well as variation in screening between drug classes
In AC&R
https://t.co/MGsWNZCiPW https://t.co/QRFq1lqWt6
Links:
ACR_Journals ACR_Journals ( View Tweet)
It's a whole new world regarding job/residency/fellowship INTERVIEWs - Whats your interview preference?
Dr. John Cush RheumNow ( View Tweet)
Machine learning of 701 Anti-Synthetase (Anti-Jo1, -PL7, -PL12, -EJ) identifies 3 Endotypes,independent Ab specificity
#1 (24%) w/ RP-ILD & high mortality
#2 (14%) dermatomyositis, intermediate prognosis
#3 (62%) arthritis & mechanics hands, good prognosis https://t.co/y9LMCfMIgN https://t.co/y0MbYlbbrV
Dr. John Cush RheumNow ( View Tweet)
Many with PsA Fail to Achieve Minimal Disease Activity
Despite the availability of numerous advanced therapies for PsA, there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study
https://t.co/OUb3bKo98v https://t.co/FDCBcdyIBm
Dr. John Cush RheumNow ( View Tweet)
Polyarteritis Nodosa (PAN): Clinical Features and Outcomes
A multinational study of PAN through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years).
https://t.co/jNNATtKTxA https://t.co/j5o6qTL2zM
Dr. John Cush RheumNow ( View Tweet)
Australian study shows self-reported difficulties w/ ambulation (limited<=1 km) had a higher risk of hip and spinal fractures (32% to 219% more)/ Included 239 000 adults >45 yrs https://t.co/5rIkDOK69u https://t.co/iJ8o0dlGlS
Dr. John Cush RheumNow ( View Tweet)
Neonatal Fc receptor mAb (lowers Igs) development:
2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis
2023 FDA approved rozanolixizumab (Rystiggo) for MG
2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG
INTERESTING? https://t.co/HB1fJet3Bo https://t.co/OBrd2Y3nye
Dr. John Cush RheumNow ( View Tweet)
Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease
The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, finds research published in the open access journal RMD Open.
https://t.co/hMlKxIDvlb https://t.co/eNEMuH4Tdc
Dr. John Cush RheumNow ( View Tweet)
Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/GBTh7UGn1O https://t.co/jlwVAbdIIF
Dr. John Cush RheumNow ( View Tweet)
EGPA: Benralizumab (BEN) or Mepolizumab (MEP)
A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA.
https://t.co/V0qWQ5nOzc https://t.co/SoOid5HKcV
Dr. John Cush RheumNow ( View Tweet)
Behçet’s Syndrome
A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches.
https://t.co/Yb3R4K9Zwf https://t.co/JAxqZ3FcQz
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA approves 10th adalimumab biosimilar - called Simlandi (adalimumab-ryvk), from Alvotech and Teva. Unique in that it's the 1st high-concentration, citrate-free & interchangeable ADA biosimilar.https://t.co/Kg7Dqr54dg https://t.co/X25SKggJzN
Dr. John Cush RheumNow ( View Tweet)
When Meningitis Strikes Twice
Amanda Moyer, MD, presents her poster at RWCS 2024.
https://t.co/hO8VkcqCkb https://t.co/9tfKI7dEs9
Dr. John Cush RheumNow ( View Tweet)
CD19 CAR T-Cell Therapy in Autoimmune Disease
The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious.
https://t.co/D53xeBdgsu https://t.co/dkrJ2CiSTl
Dr. John Cush RheumNow ( View Tweet)
Fever of Unknown Origin: Not Always an Infection
Roel Sanchez Baez, MD presents his poster at RWCS 2024.
https://t.co/WiDfcNHuNv https://t.co/gTs78QmE2A
Dr. John Cush RheumNow ( View Tweet)
Excess Cardiovascular Risk in Gout
A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.
https://t.co/ThDbAkI0VN https://t.co/uYz9Swu6sR
Dr. John Cush RheumNow ( View Tweet)
Can Biomarkers Improve Cardiovascular Risk Assessments in RA?
The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis.
https://t.co/NTI57kTtAy https://t.co/idf4qTtKcw
Dr. John Cush RheumNow ( View Tweet)
It's a Sore Subject
Cindy Chiu, DO, presents her poster at RWCS 2024.
https://t.co/Bl7mAL4grR https://t.co/9rLglObu4V
Dr. John Cush RheumNow ( View Tweet)